Key Constipation Treatment market players are focused on obtaining product approvals from regulatory bodies in order to expand their product portfolio. For example, Shire Plc., a U.S.-registered specialty biopharmaceutical company, developed Prucalopride, a selective serotonin-4 (5-HT4) receptor agonist that is administered as a once-daily, oral treatment for chronic idiopathic constipation.
Clinical trials are also a priority for major market players. In May 2019, DuPont de Nemours and Company published the findings of a randomised, controlled trial that looked at the effects of lactitol and psyllium on bowel function in constipated Indian volunteers.\
Read More:
https://knackersblogger.blogspot.com/2022/12/high-prevalence-rate-in-north-america.html
